Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Mouse , Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide derived from the C-terminal region of the human EphA2 receptor protein.|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS, pH 7.4|
|Contains||0.1% sodium azide|
|Tested Applications||Dilution *|
|Immunoprecipitation (IP)||Assay Dependent|
|Western Blot (WB)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
This gene belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. EPH and EPH-related receptors have been implicated in mediating developmental events, particularly in the nervous system. Receptors in the EPH subfamily typically have a single kinase domain and an extracellular region containing a Cys-rich domain and 2 fibronectin type III repeats. The ephrin receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. This gene encodes a protein that binds ephrin-A ligands.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC.
34-7400 was used in immunohistochemistry to study the effect of EPHA2 inhibition on cell apoptosis in non-small cell lung cancers.
|Amato KR,Wang S,Hastings AK,Youngblood VM,Santapuram PR,Chen H,Cates JM,Colvin DC,Ye F,Brantley-Sieders DM,Cook RS,Tan L,Gray NS,Chen J||The Journal of clinical investigation (124:2037)||2014|
Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome.
34-7400 was used in western blot to study eph and ephrin expression in human breast cancer and correlate it with the overall and/or recurrence-free survival.
|Brantley-Sieders DM,Jiang A,Sarma K,Badu-Nkansah A,Walter DL,Shyr Y,Chen J||PloS one (6:null)||2011|
Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells.
||Thelemann A,Petti F,Griffin G,Iwata K,Hunt T,Settinari T,Fenyo D,Gibson N,Haley JD||Molecular & cellular proteomics : MCP (4:356)||2005|
Loss of EphA2 receptor tyrosine kinase reduces ApcMin/+ tumorigenesis.
||Bogan C,Chen J,O'Sullivan MG,Cormier RT||International journal of cancer (124:1366)||2009|
CTPP1, CTRCT6, CTPA, ARCC2, ECK
ephrin type-A receptor 2, epithelial cell receptor protein tyrosine kinase, soluble EPHA2 variant 1, tyrosine-protein kinase receptor ECK, ARCC2, CTPA, CTPP1, ECK